INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2019

Nicotinamide riboside supplementation for 12 weeks did not improve endocrine pancreatic function or incretin hormones in nondiabetic men with obesity.

A 12-week randomized, double-blind, placebo-controlled trial evaluated the effects of nicotinamide riboside (NR; 1000 mg twice daily, n = 20) versus placebo (n = 20) in 40 males with obesity and insulin resistance. Supplementation with NR did not affect fasting or postchallenge levels of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Furthermore, no changes in circulating adipsin or bile acids were observed.

Study type
12-week randomized, double-blind, placebo-controlled parallel-group trial
Who was studied
40 males with obesity and insulin resistance
What was measured
β-cell and α-cell function, incretin hormones (GLP-1, GIP), glucose, insulin, C-peptide, adipsin, and bile acids

THE PAPER

Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity.

Dollerup OL, Trammell SAJ, Hartmann B, Holst JJ, Christensen B, Møller N, Gillum MP, Treebak JT, Jessen N. J Clin Endocrinol Metab, 2019.

PubMed 31390002 ↗DOI 10.1210/jc.2019-01081 ↗

Diabetes & blood sugarNutrients & adequacyWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.